• Product NameGSK1904529A
• Brief DescriptionInhibitors
• Purification98.64%
• Biological ActivityGSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
• Target NameIGF-1R inhibitor; Raf inhibitor; Syk inhibitor; VEGFR inhibitor
• CAS No. 1089283-49-7
• Calculated MW 851.96
• Formulation C44H47F2N9O5S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CCC1=CC(NC2=NC(=CC=N2)C2=C(N=C3C=CC=CN23)C2=CC(C(=O)NC3=C(F)C=CC=C3F)=C(OC)C=C2)=C(OC)C=C1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O |c:8,10,17,19,30,33,35,42,48,t:2,6,13,15,24,38,44|
  Pathways:Angiogenesis; MAPK; Tyrosine Kinase/Adaptors
  Receptor:IGF-1R; Insulin Receptor; B-Raf (V600E); Syk; VEGFR2
  Boling pt:
  Melting pt:
  Solubility:DMSO:124 mg/mL (145.54 mM)Ethanol:<1 mg/mL (<1 mM)Water<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Sabbatini P, et al. Clin Cancer Res, 2009, 15(9), 3058-3067.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting